Start Time: 10:05
End Time: 11:00
Akorn, Inc. (AKRX)
Q4 2013 Earnings Conference Call
March 3, 2014 10:00 AM ET
Raj Rai – Chief Executive Officer
Timothy A. Dick – Chief Financial Officer
NEW YORK (TheStreet) -- Akorn was falling 8.75% to $23.56 on Monday after the generic pharmaceutical company issued first-quarter guidance that came up short of analysts' expectations.
The company said it expects earnings per share of 76 cents...
Akorn (NASDAQ: AKRX) plummeted 11.98% to $22.73 after the company reported Q4 results and issued a weak FY14 guidance.
Celldex Therapeutics (NASDAQ: CLDX) dropped 11.81% to $25.77 on Q4 results. Celldex posted a Q4 loss of $0.27 per...
Below are the top drugs-generic stocks on the NASDAQ in terms of return on equity.
The trailing-twelve-month return on equity at Akorn (NASDAQ: AKRX) is 20.78%. Akorn's revenue for the same period is $304.28 million.
Akorn, Inc. (NASDAQ: AKRX), a niche generic pharmaceutical company,
today announced that it has acquired the NDA and all rights to Betimol®
(timolol ophthalmic solution) 0.25% & 0.5% from Santen. Akorn plans to
What's a departing CEO worth after a merger? Not $85 million, according to nearly 5 million Hi-Tech Pharmacal shareholders. But while an advisory vote revealed that many investors were less than enthused with CEO David Seltzer's golden parachute,...
After Monday’s trading in Akorn Inc. (AKRX) the algorithms behind MarketIntelligenceCenter.com's Artifical Intelligence Center picked out a trade that offers a 4.12% or 8.08% (for comparison purposes only), while providing 11.65% downside...
Below are the top drugs-generic stocks on the NYSE and the NASDAQ in terms of operating margin.
The trailing-twelve-month operating margin at Akorn (NASDAQ: AKRX) is 27.84%. Akorn's PEG ratio is 2.02.
The trailing-twelve-month operating...
Below are the top drugs-generic stocks on the NYSE and the NASDAQ in terms of return on assets.
The trailing-twelve-month return on assets at Akorn (NASDAQ: AKRX) is 14.50%. Akorn's PEG ratio is 1.23.
The trailing-twelve-month return on...
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Akorn (AKRX):